Ketamine's Leap from Fringe to Mainstream in Depression Treatment

A new study involving 74 participants, has demonstrated significant promise for intravenous ketamine in treating severe depression and bipolar disorder, conditions often resistant to traditional therapies. This research indicates that after just three ketamine infusions over 11 days, 52% of the participants achieved remission, with half of those frequently experiencing suicidal thoughts witnessing a dramatic decline in such impulses.